Now showing 1 - 5 of 5
  • 2015Journal Article
    [["dc.bibliographiccitation.artnumber","154272"],["dc.bibliographiccitation.journal","BioMed Research International"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Dietzel, Steffen"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T10:03:20Z"],["dc.date.available","2018-11-07T10:03:20Z"],["dc.date.issued","2015"],["dc.description.abstract","Impairment of cochlear blood flow has been discussed as factor in the pathophysiology of various inner ear disorders. However, the microscopic study of cochlear microcirculation is limited due to small scale and anatomical constraints. Here, two-photon fluorescence microscopy is applied to visualize cochlear microvessels. Guinea pigs were injected with Fluorescein isothiocyanateor Texas red-dextrane as plasma marker. Intravital microscopy was performed in four animals and explanted cochleae from four animals were studied. The vascular architecture of the cochlea was visualized up to a depth of 90.0 +/- 22.7 mu m. Imaging yielded a mean contrast-to-noise ratio (CNR) of 3.3 +/- 1.7. Mean diameter in vivo was 16.5 +/- 6.0 mu m for arterioles and 8.0 +/- 2.4 mu m for capillaries. In explanted cochleae, the diameter of radiating arterioles and capillaries was measured with 12.2 +/- 1.6 mu m and 6.6 +/- 1.0 mu m, respectively. The difference between capillaries and arterioles was statistically significant in both experimental setups (P < 0.001 and P = 0.022, two-way ANOVA). Measured vessel diameters in vivo and ex vivo were in agreement with published data. We conclude that two-photon fluorescence microscopy allows the investigation of cochlear microvessels and is potentially a valuable tool for inner ear research."],["dc.description.sponsorship","Open Access Publikationsfonds 2015"],["dc.identifier.doi","10.1155/2015/154272"],["dc.identifier.isi","000353163300001"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11857"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38437"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Hindawi Publishing Corp"],["dc.relation.issn","2314-6141"],["dc.relation.issn","2314-6133"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.title","Two-Photon Microscopy Allows Imaging and Characterization of Cochlear Microvasculature In Vivo"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI WOS
  • 2012Journal Article
    [["dc.bibliographiccitation.firstpage","72"],["dc.bibliographiccitation.journal","Brain"],["dc.bibliographiccitation.lastpage","87"],["dc.bibliographiccitation.volume","135"],["dc.contributor.author","Fledrich, Robert"],["dc.contributor.author","Schlotter-Weigel, Beate"],["dc.contributor.author","Schnizer, Tuuli J."],["dc.contributor.author","Wichert, Sven P."],["dc.contributor.author","Stassart, Ruth Martha"],["dc.contributor.author","Hoerste, Gerd Meyer Zu"],["dc.contributor.author","Klink, Axel"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Haag, Uwe"],["dc.contributor.author","Walter, Maggie C."],["dc.contributor.author","Rautenstrauss, Bernd"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Rossner, Moritz J."],["dc.contributor.author","Sereda, Michael W."],["dc.date.accessioned","2018-11-07T09:15:45Z"],["dc.date.available","2018-11-07T09:15:45Z"],["dc.date.issued","2012"],["dc.description.abstract","Charcot-Marie-Tooth disease is the most common inherited neuropathy and a duplication of the peripheral myelin protein 22 gene causes the most frequent subform Charcot-Marie-Tooth 1A. Patients develop a slowly progressive dysmyelinating and demyelinating peripheral neuropathy and distally pronounced muscle atrophy. The amount of axonal loss determines disease severity. Although patients share an identical monogenetic defect, the disease progression is strikingly variable and the impending disease course can not be predicted in individual patients. Despite promising experimental data, recent therapy trials have failed. Established clinical outcome measures are thought to be too insensitive to detect amelioration within trials. Surrogate biomarkers of disease severity in Charcot-Marie-Tooth 1A are thus urgently needed. Peripheral myelin protein 22 transgenic rats harbouring additional copies of the peripheral myelin protein 22 gene ('Charcot-Marie-Tooth rats'), which were kept on an outbred background mimic disease hallmarks and phenocopy the variable disease severity of patients with Charcot-Marie-Tooth 1A. Hence, we used the Charcot-Marie-Tooth rat to dissect prospective and surrogate markers of disease severity derived from sciatic nerve and skin tissue messenger RNA extracts. Gene set enrichment analysis of sciatic nerve transcriptomes revealed that dysregulation of lipid metabolism associated genes such as peroxisome proliferator-activated receptor gamma constitutes a modifier of present and future disease severity. Importantly, we directly validated disease severity markers from the Charcot-Marie-Tooth rats in 46 patients with Charcot-Marie-Tooth 1A. Our data suggest that the combination of age and cutaneous messenger RNA levels of glutathione S-transferase theta 2 and cathepsin A composes a strong indicator of disease severity in patients with Charcot-Marie-Tooth 1A, as quantified by the Charcot-Marie-Tooth Neuropathy Score. This translational approach, utilizing a transgenic animal model, demonstrates that transcriptional analysis of skin biopsy is suitable to identify biomarkers of Charcot-Marie-Tooth 1A."],["dc.identifier.doi","10.1093/brain/awr322"],["dc.identifier.isi","000300044400016"],["dc.identifier.pmid","22189569"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13524"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27771"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","0006-8950"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2019Journal Article
    [["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","The Laryngoscope"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","130"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Anczykowski, Mahalia Z."],["dc.contributor.author","Flach, Susanne"],["dc.contributor.author","Spiegel, Jennifer L."],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Ihler, Friedrich"],["dc.date.accessioned","2020-01-14T09:01:11Z"],["dc.date.accessioned","2021-10-27T13:22:03Z"],["dc.date.available","2020-01-14T09:01:11Z"],["dc.date.available","2021-10-27T13:22:03Z"],["dc.date.issued","2019"],["dc.description.abstract","OBJECTIVES/HYPOTHESIS: Indication for postoperative radiotherapy in patients with locally circumscribed tumors (pT1-pT2) and a single ipsilateral lymph node metastasis (pN1) is debatable. The aim of this study was to evaluate the oncological long-term outcome of patients with pT1-pT2 pN1 squamous cell carcinoma (SCC) of the oral cavity, the oropharynx, and the hypopharynx without extracapsular spread (ECS) after a margin-negative surgical resection, who either received or did not receive postoperative (chemo)radiotherapy. STUDY DESIGN: Retrospective case series. METHODS: The oncological outcome of patients with pT1-pT2 pN1 SCC without ECS was evaluated retrospectively. All patients underwent primary tumor resection that included transoral laser microsurgery and neck dissection at an academic tertiary referral center. RESULTS: Of 65 identified patients treated between 1986 and 2015 (18 oral cavity, 30 oropharynx, 17 hypopharynx), 21 (32%) received postoperative radiotherapy, and 44 (68%) were treated by surgery alone. The group of patients receiving postoperative treatment showed a significantly superior 5-year disease-specific (94.4% vs. 73.2%, P = .029) and recurrence-free survival (85.2% vs. 43.2%, P = .002), as well as a higher local control rate (90.2% vs. 64.9%, P = .042). The overall survival was 71.4% vs. 62.6% (P = .53). The mean follow-up was 80.7 months. CONCLUSIONS: Patients with locally circumscribed carcinomas and a single ipsilateral ECS-negative lymph node metastasis seem to benefit from postoperative radiotherapy. LEVEL OF EVIDENCE: 4 Laryngoscope, 2019."],["dc.identifier.doi","10.1002/lary.28394"],["dc.identifier.eissn","1531-4995"],["dc.identifier.issn","0023-852X"],["dc.identifier.pmid","31837151"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92065"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1531-4995"],["dc.relation.issn","1531-4995"],["dc.relation.issn","0023-852X"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","Benefit of postoperative radiotherapy for early tumors with single ipsilateral lymph node metastasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2016Journal Article
    [["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Trends in Hearing"],["dc.bibliographiccitation.lastpage","12"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Ihler, F."],["dc.contributor.author","Blum, J."],["dc.contributor.author","Berger, M.-U."],["dc.contributor.author","Weiss, B. G."],["dc.contributor.author","Welz, C."],["dc.contributor.author","Canis, M."],["dc.date.accessioned","2019-07-09T11:42:57Z"],["dc.date.available","2019-07-09T11:42:57Z"],["dc.date.issued","2016"],["dc.description.abstract","Semi-implantable transcutaneous bone conduction devices are treatment options for conductive and mixed hearing loss (CHL/MHL). For counseling of patients, realistic simulation of the functional result is desirable. This study compared speech recognition in noise with a semi-implantable transcutaneous bone conduction device to external stimulation with a bone conduction device fixed by a headband. Eight German-language adult patients were enrolled after a semi-implantable transcutaneous bone conduction device (Bonebridge, Med-El) was implanted and fitted. Patients received a bone conduction device for external stimulation (Baha BP110, Cochlear) fixed by a headband for comparison. The main outcome measure was speech recognition in noise (Oldenburg Sentence Test). Pure-tone audiometry was performed and subjective benefit was assessed using the Glasgow Benefit Inventory and Abbreviated Profile of Hearing Aid Benefit questionnaires. Unaided, patients showed a mean signal-to-noise ratio threshold of 4.6 4.2 dB S/N for speech recognition. The aided results were 3.3 7.2 dB S/N by external bone conduction stimulation and 1.2 4.0 dB S/N by the semi-implantable bone conduction device. The difference between the two devices was not statistically significant, while the difference was significant between unaided and aided situation for both devices. Both questionnaires for subjective benefit favored the semiimplantable device over external stimulation. We conclude that it is possible to simulate the result of speech recognition in noise with a semi-implantable transcutaneous bone conduction device by external stimulation. This should be part of preoperative counseling of patients with CHL/MHL before implantation of a bone conduction device."],["dc.identifier.doi","10.1177/2331216516669330"],["dc.identifier.pmid","27698259"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14017"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58795"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2331-2165"],["dc.rights","CC BY-NC 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/3.0"],["dc.title","The Prediction of Speech Recognition in Noise With a Semi-Implantable Bone Conduction Hearing System by External Bone Conduction Stimulation With Headband: A Prospective Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2018Journal Article
    [["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","BioMed Research International"],["dc.bibliographiccitation.lastpage","12"],["dc.bibliographiccitation.volume","2018"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Gratz, Ronja"],["dc.contributor.author","Wolff, Hendrik A."],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Salinas, Gabriela"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2019-07-09T11:45:12Z"],["dc.date.available","2019-07-09T11:45:12Z"],["dc.date.issued","2018"],["dc.description.abstract","In epithelial tumors, a shift towards a mesenchymal phenotype has been associated with increased invasiveness andmetastasis. It is assumed that this phenomenon plays amajor role in disease progression and ultimately prognosis.This study investigated epithelialmesenchymal transition (EMT) in human papillomavirus- (HPV-) negative pharyngeal squamous cell carcinoma. Tissue was obtained from one hypopharyngeal primary tumor and a regional lymph nodemetastasis during surgery with curative intention. A cell culture was established fromthe primary tumor andmesenchymal growth conditions were emulated.Gene expression profiling was performed (Human 8 × 60K design array, Agilent Technologies) and EMT was assessed by a gene set (MSigDB: M5930, Hallmark epithelial mesenchymal transition), applying gene set expression analysis (GSEA). Immunohistochemical staining and flow cytometry of CD44 and E-cadherin were compared in primary tumor, metastasis, and cell cultures. Primary tumor and metastasis were highly positive for CD44.Aloss of E-cadherin occurred in the metastasis. Flowcytometry showed the appearance of a population without E-cadherin in spheroid colonies. In GSEA, the EMT phenotype was enriched in the primary tumor compared to metastasis and cell cultures (FDR < 25%, 𝑝 < 5%). EMT showed variable expression during metastasis. It may thereby be a dynamic state in HPV-negative pharyngeal squamous cell carcinoma that is active only during the process of metastasis itself. Thereby, the primary tumor as well as the metastasis may exhibit fewer EMT properties."],["dc.identifier.doi","10.1155/2018/7929104"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15055"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59179"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2314-6141"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Epithelial-Mesenchymal Transition during Metastasis of HPV-Negative Pharyngeal Squamous Cell Carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI